Key result
MRAs reduce mortality and readmissions in HFrEF and hospitalizations in HFpEF but remain underutilized.
Why the study?
Heart failure causes significant global morbidity and mortality, prompting an evaluation of the benefits, potential risks, and role of mineralocorticoid receptor antagonists in both HFpEF and HFrEF.
Do mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalizations in patients with HFpEF and HFrEF?
Do mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalizations in patients with HFpEF and HFrEF?
This narrative review highlights that MRAs improve outcomes in both HFpEF and HFrEF but remain underutilized in clinical practice despite strong guideline recommendations.
Supports considering MRAs more often in HF; confirms benefits across phenotypes while leaving utilization gaps open for study.
Background: Heart failure is a major cause of morbidity and mortality globally. By the end of this decade, ~8 million Americans will have heart failure with an expenditure of $69.8 billion. Objective: In this narrative review, we evaluate the benefits, potential risks and the role of mineralocorticoid receptor antagonists (MRAs) in the management of both Heart Failure with Preserved Ejection Fraction (HFpEF) and Heart Failure with Reduced Ejection Fraction (HFrEF). Methods: We performed a comprehensive literature review to assess the available evidence on the role of MRAs in heart failure using the online databases (PubMed, Embase, Scopus, CINAHL and Google Scholar). Results: Clinical evidence shows that MRAs such as spironolactone and eplerenone reduce mortality and readmissions for patients with HFrEF compared with placebo. Furthermore, one trial reported that MRAs reduce heart failure hospitalization in patients with HFpEF. The American College of Cardiology/American Heart Association Guidelines strongly recommend using MRA in patients with reduced left ventricular ejection fraction (LVEF) with Class II-IV symptoms, estimated glomerular filtration rate >30 ml/min/1.73 m2, and absence of hyperkalemia. Despite this, MRAs are underutilized in the management of heart failure. Conclusions: MRAs improve outcomes in patients with both HFpEF and HFrEF but remain underutilized.
No takes yet. Share an insight, caveat, or question.
Mares et al. (2021) conducted a review in Heart Failure with Preserved Ejection Fraction (HFpEF) and Heart Failure with Reduced Ejection Fraction (HFrEF). Mineralocorticoid receptor antagonists (MRAs) vs. Placebo was evaluated. Mineralocorticoid receptor antagonists reduce mortality and readmissions in HFrEF compared with placebo and reduce hospitalizations in HFpEF, but remain underutilized in clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: